Medicare agrees to pay for $93,000 prostate cancer drug
WASHINGTON - Medicare officials said Wednesday that the program would pay the $93,000 cost of the prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live.
The Centers for Medicare and Medicaid said the biotech drug made by Dendreon Corp. was a "reasonable and necessary" medicine. The decision ensures that millions of men would be able to afford the drug through the government-backed health-care coverage. With government reimbursement, analysts estimate Provenge could total $1 billion in sales next year.
Medicare is legally prohibited from considering price when deciding whether to pay for a new treatment. The Food and Drug Administration approved Provenge last April and in most cases Medicare automatically covers drugs cleared by the agency. But Medicare's decision to review Provenge last year prompted outrage from some patients and doctors who said the government was looking for a reason to avoid reimbursing for the pricey drug.
The infused drug is a first-of-a-kind treatment in that each dose is customized to work with a patient's immune system. Seattle-based Dendreon says Provenge's price reflects the more than $1 billion spent researching and developing the drug. And prostate cancer patients point out that the median survival time with Provenge is double that of chemotherapy, which is about two months and has significant side effects.
"It's impossible to put a dollar figure on a human life, especially when you're talking about a drug that has such mild side effects," said Jim Kiefert, a prostate cancer patient and advocate who was part of the Provenge study.
Bioethicists who study health-care decisions say Medicare's ruling on Provenge mirrors the bias of the overall U.S. health system, which emphasizes expensive treatments over basic medical care. Health-care costs account for nearly one fifth of the U.S. economy, more than any other country.
"We tend to put our health-care dollars into very high-tech interventions that produce very marginal improvements," said Steven Miles, a professor at the University of Minnesota's Center for Bioethics. "The problem is that we have created a health-care system that is uniquely inadequate in terms of access to primary health care, which is where you get the most bang for your buck."
A growing number of biologically engineered cancer drugs are being priced in the $100,000 range, including therapies from Roche and Eli Lilly & Co. Last week, Bristol-Myers Squibb Co. received approval for a new melanoma drug that will be priced at roughly $120,000 per patient.
Be the first one to comment on this news